Table 1

Baseline patient characteristics

CharacteristicPlacebo twice daily200 mg celecoxib twice daily400 mg celecoxib twice daily
All APC trial participantsn = 679n = 685n = 671
Age (y) mean (range)59 (31-88)59 (35-83)59 (34-87)
Male sex; no. (%)473 (69.7)460 (67.2)454 (67.7)
Mean body mass index (kg/m2)28.8(M) 29.3 (F)28.9 (M) 28.5 (F)28.6 (M) 29.0 (F)
Race or ethnic group (%)
 Non-Hispanic White624 (91.9)632 (92.3)607 (90.5)
 Non-Hispanic Black37 (5.4)30 (4.4)45 (6.7)
 Hispanic11 (1.6)16 (2.3)10 (1.5)
 Asian, Pacific Islander, or other7 (1.0)7 (1.0)9 (1.3)
CRC in a parent (%)140 (20.6)147 (21.5)142 (21.2)
No of reported adenomas2.0 ± 0.12.1 ± 0.12.1 ± 0.1
At least one adenoma ≥1 cm (%)288 (42.4)303 (44.2)291 (43.4)
Multiple adenomas;no of patients (%)374 (55.1)375 (54.7)363 (54.1)
Adenoma burden, (cm)*1.48 ± 0.051.50 ± 0.051.47 ± 0.04
Use of low-dose aspirin (%)212 (31.2)211 (30.8)204 (30.4)
History of cardiovascular events(%)99 (14.6)94 (13.7)99 (14.8)
History of hypertension (%)280 (41.2)290 (42.3)264 (39.3)
History of diabetes (%)61 (9.0)67 (9.8)66 (9.8)
Current cigarette smoker (%)122 (18.0)119 (17.4)96 (14.3)
All APC trial extension study participantsn = 307n = 311n = 315
Age (y) mean (range)59 (31-88)59 (35-83)59 (34-87)
Male sex (%)222 (72.3)221 (71.1)215 (68.3)
Mean BMI (kg/m2)28.7 (M) 28.6 (F)28.3 (M) 27.8 (F)28.6 (M) 29.0 (F)
Race or ethnic group (%)
 Non-Hispanic White289 (94.1)291 (93.6)287 (91.1)
 Non-Hispanic Black10 (3.3)10 (3.2)21 (6.6)
 Hispanic4 (1.3)8 (2.6)3 (1.0)
 Asian, Pacific Islander, or other4 (1.3)2 (0.6)4 (1.3)
APC trial extension study participants wth year 5 colonoscopy resultsn = 214n = 207n = 218
Age (y) mean (range)59 (35-88)59 (35-79)59 (38-79)
Male sex (%)148 (69.2)152 (73.4)155 (71.1)
Mean BMI (kg/m2)28.7 (M) 28.6 (F)28.3 (M) 28.2 (F)28.9 (M) 28.9 (F)
CRC in a parent (%)57 (26.6)45 (21.7)48 (22.0)
No of reported adenomas at baseline, mean (SE)2.2 (0.1)2.1 (0.1)2.1 (0.1)
At least one adenoma ≥1 cm at baseline (%)82 (38.3)88 (42.5)74 (43.1)
Multiple adenomas at baseline (%)120 (56.1)115 (55.6)119 (55.3)
Adenoma burden at baseline*, mean (SE)1.51 (0.09)1.51 (0.10)1.47 (0.08)
  • *Defined as sum of diameter of all adenomas, in cm.

  • Low-dose aspirin = ≤100 mg per day or 325 mg every other day.

  • Defined as a history of angina, myocardial infarction, coronary artery disease, congestive heart failure, or cerebrovascular disease.